Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Britain Courts Anthropic Amid US Defense Department Dispute 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Apple Turns 50: From Garage Startup to AI Crossroads 
ATLANTA, July 24, 2017 -- Alimera Sciences (NASDAQ:ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the second quarter ended June 30, 2017, after the close of the financial markets on Wednesday, August 2, 2017.
An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. The call will be held at 9:00 AM ET, on Thursday, August 3, 2017. Please refer to the information below for conference call dial-in information and webcast registration.
Conference Details
Conference date: Thursday, August 3, 2017 9:00AM ET
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: Alimera Sciences' Second Quarter 2017 Results Call
Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website, www.alimerasciences.com, under "Investor Relations".
About Alimera Sciences
Alimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in its product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
Contact CG CAPITAL Rich Cockrell 877.889.1972 [email protected]
